Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
Table 1
Baseline characteristics of all recruited AKI patients.
Baseline characteristics of all recruited AKI patients (274)
Median values and IQR unless otherwise stated
Median age (years) (IQR)
64 (53–72)
Sex (female), N (%)
114 (41.6)
Length of stay (days) (IQR)
6 (3–12)
SAPS-2 score (IQR)
48.5 (38–64)
Invasive ventilation, N (%)
109 (40)
Dialysis on ICU, N (%)
66 (24)
Maximum urea (mmol/l) (IQR)
15.7 (9–25.2)
Baseline creatinine
N measured (%)
156 (56.9)
Measured (µmol/l) (IQR)
64 (50.5–76)
Estimateda (µmol/l) (IQR)
88 (71–97)
N = 146
Admission creatinine (µmol/l) (IQR)
135 (104–213)
Maximum creatinine (µmol/l) (IQR)
169.5 (122–263)
Last ICU creatinine (µmol/l) (IQR)
107 (72–149.5)
Admission cystatin C (mg/l) (IQR)
1.58 (1.1–2.35)
Maximum cystatin C (mg/l) (IQR)
2.14 (1.44–3.04)
Last ICU cystatin C (mg/l) (IQR)
1.65 (1.23–2.21)
Discharge creatinine/cystatin C ratio (IQR)
7.1 (5.2–9.2)
COPD
53 (14.5)
Diabetes mellitus I and II
54 (19.7)
Cardiovascular disease
90 (33.0)
Hypertension
120 (44.0)
Liver failure
99 (36.0)
Haematological malignancy
19 (6.9)
Other malignancies
84 (30.6)
Heart failure
38 (13.8)
MDRD = modified diet in renal disease formula. aCreatinine was estimated using the Modified Diet in Renal Disease (MDRD) formula using an expecting GFR of 75 ml/kg/min/1.73 m2.
